Teresa Parli
Overview
Explore the profile of Teresa Parli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
305
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhatt D, Bays H, Miller M, Cain 3rd J, Wasilewska K, Andrawis N, et al.
Nat Med
. 2024 Mar;
30(6):1788-1789.
PMID: 38438737
No abstract available.
2.
Bhatt D, Bays H, Miller M, Cain 3rd J, Wasilewska K, Andrawis N, et al.
Nat Med
. 2023 Jun;
29(7):1782-1792.
PMID: 37355760
Pegozafermin, a long-acting glycopegylated analog of human fibroblast growth factor 21, is in development for the treatment of severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis. Here we report the results of...
3.
Armstrong A, Lin P, Tombal B, Saad F, Higano C, Joshua A, et al.
Eur Urol
. 2020 Jun;
78(3):347-357.
PMID: 32527692
Background: In the PREVAIL study, enzalutamide significantly improved clinical outcomes versus placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). Objective: To evaluate long-term benefits and risks of enzalutamide...
4.
Armstrong A, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J, et al.
JAMA Oncol
. 2019 Dec;
6(2):217-225.
PMID: 31830211
Importance: For men with metastatic castration-resistant prostate cancer (mCRPC) whose condition is responding to enzalutamide, new unconfirmed bone lesions detected at posttreatment scinitigraphy may reflect an osteoblastic reaction that represents...
5.
Armstrong A, Lin P, Higano C, Iversen P, Sternberg C, Tombal B, et al.
Eur Urol Oncol
. 2019 Jul;
2(6):677-684.
PMID: 31274110
Background: In the PREVAIL study, enzalutamide provided significant improvements versus placebo in clinical outcomes in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC). The association of post-treatment prostate-specific antigen (PSA)...
6.
Rathkopf D, Beer T, Loriot Y, Higano C, Armstrong A, Sternberg C, et al.
JAMA Oncol
. 2018 Mar;
4(5):694-701.
PMID: 29522174
Importance: Drug development for metastatic castration-resistant prostate cancer has been limited by a lack of clinically relevant trial end points short of overall survival (OS). Radiographic progression-free survival (rPFS) as...
7.
Taplin M, Armstrong A, Lin P, Krivoshik A, Phung D, Parli T, et al.
J Urol
. 2017 Jul;
198(6):1324-1332.
PMID: 28736322
Purpose: Metastatic castration resistant prostate cancer with low baseline prostate specific antigen represents an early stage in the natural history of castration resistant prostate cancer progression (low volume disease), low...
8.
Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer T, et al.
Health Qual Life Outcomes
. 2017 Jun;
15(1):130.
PMID: 28645287
Background: The effect of enzalutamide on health-related quality of life (HRQoL) in the PREVAIL trial in chemotherapy-naïve men with metastatic castration-resistant prostate cancer was analyzed using the generic EQ-5D instrument....
9.
Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C, et al.
Eur Urol
. 2016 Aug;
71(2):151-154.
PMID: 27477525
Patient Summary: According to data from longer follow-up, enzalutamide continued to provide benefit over placebo in patients with metastatic castration-resistant prostate cancer.